Press releases
Latest news
November 20, 2024
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Read more
November 09, 2024
Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST’s 17th Annual Global Science Summit
Read more
November 05, 2024
Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update
Read more
October 29, 2024
Ultragenyx to Host Conference Call for Third Quarter 2024 Financial Results and Corporate Update
Read more
October 07, 2024
Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis Imperfecta
Read more
October 03, 2024
Ultragenyx Provides Update on Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
Read more
September 26, 2024
Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual Meeting
Read more
September 18, 2024
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Read more
Displaying 1 - 10 of 10